stockgist
HomeTop MoversCompaniesConcepts

Market

  • Top Movers
  • Companies
  • Concepts

SEC Filings

  • AI Filing Analysis
  • Financial Reports
  • Current Reports
  • IPO Filings

Ownership

  • Institutional Holdings
  • Insider Trading

About

  • Data updates every 5 min
  • SEC EDGAR Source
© 2025–2026 StockGist|Information only, not investment advice
    1. Filing Summaries
    stockgist
    HomeTop MoversCompaniesConcepts

    AI-Generated Filing Summaries

    AI-powered insights from 8-K, 6-K, 10-K and 10-Q filings with category and key takeaways

    Past 24 Hours

    Total

    430

    10-K

    13

    10-Q

    10

    8-K

    239

    6-K

    145

    13F

    0

    Other

    23

    Materiality:

    Showing 20 of 15950 summaries

    MainStreet Bancshares, Inc.

    MNSBP
    8-K

    Filing ID: 786823 • Mar 25, 2026, 11:00 AM ET

    Subsidiary Bank Director Appointment
    MEDIUM
    7.01
    •

    Morgan Higgins appointed as Director of MainStreet Bank on March 25, 2026.

    •

    Ms. Higgins is Partner at Blue Delta Capital Partners, leading equity investments in government contracting businesses.

    •

    Prior to Blue Delta, Ms. Higgins was Executive Director at JP Morgan Chase, focusing on aerospace and government services banking.

    MainStreet Bancshares, Inc. issued a press release announcing the appointment of Morgan Higgins to MainStreet Bank's Board of Directors. Ms. Higgins brings over 20 years of experience in banking and government contracting, including roles at Blue Delta Capital Partners and JP Morgan Chase, to support the Bank's growth in defense and government services markets.

    View Filing

    Bluerock Homes Trust, Inc.

    BHM
    8-K

    Filing ID: 786821 • Mar 25, 2026, 10:50 AM ET

    Governance Disclosures (Part III Items 10-14 Incorporation)
    LOW
    •

    Filed Post-Effective Amendment No. 1 to Form S-11 (Reg. No. 333-290772) on March 12, 2026, including 2025 Form 10-K financials.

    •

    Executive officers include R. Ramin Kamfar (CEO, age 62), Jordan Ruddy (President, age 63), Ryan S. MacDonald (CIO, age 43).

    •

    Board of directors: R. Ramin Kamfar (Chairman/CEO), I. Bobby Majumder (Lead Independent), Elizabeth Harrison, Kamal Jafarnia, Romano Tio (all independent except Kamfar).

    Bluerock Homes Trust, Inc. filed this Form 8-K under Item 8.01 to incorporate by reference into its Form S-11 Registration Statement (effective December 10, 2025) and upcoming 2026 Proxy Statement certain Part III disclosures, including executive officers, board of directors, governance, director compensation, security ownership, related party transactions, and accountant fees. This updates the Registration Statement with audited 2025 financials and provides investor transparency on governance and affiliations.

    View Filing

    Sony Group Corporation

    SONY
    6-K

    Filing ID: 786825 • Mar 25, 2026, 11:10 AM ET

    Share Repurchase Conclusion
    MEDIUM
    •

    Total shares repurchased: 70,793,900 shares

    •

    Total purchase amount: 249,999,854,281 yen

    •

    Recent repurchase (March 1-24, 2026): 33,585,600 shares for 112,944,325,662 yen

    Sony Group Corporation announced the status and conclusion of its repurchase of common stock under board resolutions dated November 11, 2025, February 5, 2026, and February 26, 2026. As of March 24, 2026, Sony repurchased 70,793,900 shares for 249,999,854,281 yen via open market purchases on the Tokyo Stock Exchange.

    View Filing

    Sony Group Corporation

    SNEJF
    6-K

    Filing ID: 786825 • Mar 25, 2026, 11:10 AM ET

    Share Repurchase Conclusion
    MEDIUM
    •

    Total shares repurchased: 70,793,900 shares

    •

    Total purchase amount: 249,999,854,281 yen

    •

    Recent repurchase (March 1-24, 2026): 33,585,600 shares for 112,944,325,662 yen

    Sony Group Corporation announced the status and conclusion of its repurchase of common stock under board resolutions dated November 11, 2025, February 5, 2026, and February 26, 2026. As of March 24, 2026, Sony repurchased 70,793,900 shares for 249,999,854,281 yen via open market purchases on the Tokyo Stock Exchange.

    View Filing

    Zentek Ltd.

    ZTEK
    6-K

    Filing ID: 786819 • Mar 25, 2026, 10:40 AM ET

    Subsidiary CRO Services Launch
    MEDIUM
    •

    Triera Biosciences plans to begin CRO services for custom aptamer discovery via SELEX, biosensor engineering, and ML classification.

    •

    Exclusive worldwide royalty-bearing license from McMaster University for 20 years on aptamer applications developed with Dr. Yingfu Li's team.

    •

    Services targeted at pharmaceutical, biotechnology, and diagnostics organizations in Canada, United States, and Europe.

    Zentek Ltd. announced that its wholly-owned subsidiary Triera Biosciences plans to offer contract research organization services for custom aptamer discovery, biosensor enablement, and machine-learning classification, backed by an exclusive 20-year worldwide royalty-bearing license from McMaster University. This targets high-priority infectious disease and oncology detection markets to generate client-funded revenue while retaining IP ownership.

    View Filing

    Vodafone Group Public Limited Company

    VOD
    6-K

    Filing ID: 786822 • Mar 25, 2026, 11:00 AM ET

    Block Admission Application
    LOW
    •

    Total shares for admission: 286,113,801 ordinary shares of US$0.20 20/21 each

    •

    Admission expected: on or around 31 March 2026

    •

    285,963,801 shares under Vodafone Group Plc Global Incentive Plan 2023

    Vodafone Group Plc applied to the London Stock Exchange for admission of 286,113,801 ordinary shares of US$0.20 20/21 each to the Official List, expected on or around 31 March 2026. Of these, 285,963,801 shares are issued under the Vodafone Group Plc Global Incentive Plan 2023 and 150,000 under the Vodafone Group Plc AirTouch 1999 Exchange Programme, both ranking pari passu with existing shares.

    View Filing

    Vodafone Group Public Limited Company

    VODPF
    6-K

    Filing ID: 786822 • Mar 25, 2026, 11:00 AM ET

    Block Admission Application
    LOW
    •

    Total shares for admission: 286,113,801 ordinary shares of US$0.20 20/21 each

    •

    Admission expected: on or around 31 March 2026

    •

    285,963,801 shares under Vodafone Group Plc Global Incentive Plan 2023

    Vodafone Group Plc applied to the London Stock Exchange for admission of 286,113,801 ordinary shares of US$0.20 20/21 each to the Official List, expected on or around 31 March 2026. Of these, 285,963,801 shares are issued under the Vodafone Group Plc Global Incentive Plan 2023 and 150,000 under the Vodafone Group Plc AirTouch 1999 Exchange Programme, both ranking pari passu with existing shares.

    View Filing

    Limitless Projects Inc.

    10-Q

    Filing ID: 786839 • Mar 25, 2026, 12:10 PM ET

    •

    Six-month net loss $7,224, improved 48% from $13,835 YoY.

    •

    Total assets $151,601, up $12,000 QoQ from July 31, 2025.

    •

    Accounts payable $562,154, increased $19,224 in six months.

    Limitless Projects Inc., a software development company, reported no revenue for the six months ended January 31, 2026, matching the prior year period with zero general income. The consolidated net loss narrowed to $7,224 from $13,835 year-over-year, driven by reduced general and administrative expenses of $7,224 versus $13,835. For the three months ended January 31, 2026 (Q2), operating loss was $3,612, improved from $7,727 in Q2 2025. Total assets grew to $151,601 from $139,601 at July 31, 2025, reflecting $12,000 in software development costs, increasing software assets to $139,430. Liabilities rose to $562,154 from $542,930, primarily accounts payable up $19,224. Stockholders' equity deficit expanded slightly to -$410,553 from -$403,329, with accumulated deficit at -$305,917. Cash remained at $0, with net operating cash flow of $12,000 from payables increase offsetting losses, fully offset by $12,000 investing outflow. No financing activities. The filing highlights substantial going concern doubt due to losses and liquidity needs, with management relying on potential public offering proceeds and future software revenue from products like Privacy and Value and WarpSpeed Taxi. Internal controls over financial reporting were not effective as of January 31, 2026.

    View Filing

    Ford Credit Auto Owner Trust 2026-A

    8-K

    Filing ID: 786830 • Mar 25, 2026, 11:30 AM ET

    Entry into Material Definitive Agreements for Asset-Backed Securities Issuance
    HIGH
    1.01
    •

    Issuer: Ford Credit Auto Owner Trust 2026-A; Depositor: Ford Credit Auto Receivables Two LLC; Sponsor/Servicer: Ford Motor Credit Company LLC.

    •

    Notes issued: Class A-1 ($297,000,000 at 3.826%), A-2a ($253,000,000 at 4.02%), A-2b ($253,000,000 at SOFR+0.43%), A-3 ($469,000,000 at 4.05%), A-4 ($78,000,000 at 4.16%), B ($42,630,000 at 4.34%), C ($28,410,000 at 0.00%).

    •

    Agreements dated March 1, 2026; Prospectus dated March 17, 2026.

    Ford Credit Auto Owner Trust 2026-A entered into an Indenture and related Transaction Documents, including the Trust Agreement, Receivables Purchase Agreement, and Sale and Servicing Agreement, for the issuance of asset-backed Notes secured by a pool of auto receivables with a purchase price of $1,386,583,195.90. This securitization enables structured financing backed by retail installment contracts originated by Ford Motor Credit Company LLC.

    View Filing

    GH Research PLC

    GHRS
    6-K

    Filing ID: 786827 • Mar 25, 2026, 11:20 AM ET

    Phase 2b Clinical Trial Results Publication
    HIGH
    •

    Phase 2b primary endpoint met: MADRS reduction -15.5 points vs placebo on Day 8 (P<0.0001)

    •

    Day 8 remission rate 57.5% GH001 vs 0% placebo

    •

    JAMA Psychiatry publication DOI: 10.1001/jamapsychiatry.2026.0096 includes full results and 6-month OLE data

    GH Research PLC announced the peer-reviewed publication of Phase 2b trial results for GH001 (mebufotenin) in treatment-resistant depression in JAMA Psychiatry, confirming MADRS reduction of -15.5 points vs placebo on Day 8 (P<0.0001) and 57.5% Day 8 remission rate. A new post-hoc analysis shows efficacy independent of prior lifetime antidepressant failures, with Day 8 remission rates of 53.9%-63.6% across subgroups.

    View Filing

    Sony Group Corporation

    SNEJF
    6-K

    Filing ID: 786824 • Mar 25, 2026, 11:10 AM ET

    Discontinuation of EV Models Development and Business Direction Review
    MEDIUM
    •

    SHM discontinues development and launch of AFEELA 1 and second model announced March 25, 2026

    •

    Decision follows Honda's automobile electrification strategy reassessment on March 12, 2026

    •

    SHM to issue full refunds of reservation fees for AFEELA 1 in California

    Sony Group Corporation, Honda Motor Co., Ltd., and their joint venture Sony Honda Mobility Inc. (SHM) announced the discontinuation of development and launch of SHM's AFEELA 1 and second AFEELA-branded EV models, and will review SHM's business direction due to changes in Honda's EV strategy. Sony, which accounts for SHM under the equity method, states the impact will not be material to its consolidated results for fiscal years ending March 2026 and 2027.

    View Filing

    Sony Group Corporation

    SONY
    6-K

    Filing ID: 786824 • Mar 25, 2026, 11:10 AM ET

    Discontinuation of EV Models Development and Business Direction Review
    MEDIUM
    •

    SHM discontinues development and launch of AFEELA 1 and second model announced March 25, 2026

    •

    Decision follows Honda's automobile electrification strategy reassessment on March 12, 2026

    •

    SHM to issue full refunds of reservation fees for AFEELA 1 in California

    Sony Group Corporation, Honda Motor Co., Ltd., and their joint venture Sony Honda Mobility Inc. (SHM) announced the discontinuation of development and launch of SHM's AFEELA 1 and second AFEELA-branded EV models, and will review SHM's business direction due to changes in Honda's EV strategy. Sony, which accounts for SHM under the equity method, states the impact will not be material to its consolidated results for fiscal years ending March 2026 and 2027.

    View Filing

    Nanobiotix S.A.

    NBTX
    6-K

    Filing ID: 786829 • Mar 25, 2026, 11:30 AM ET

    Statement Regarding Recent Media Speculation on Potential Takeover
    LOW
    •

    Nanobiotix denies any intention to acquire control of the Company.

    •

    No process or assessment toward a takeover is being conducted.

    •

    Factual inaccuracies in media report not consistent with Company's recent public disclosures.

    Nanobiotix issued a statement denying recent media speculation about a potential public takeover, stating to the best of its knowledge there is no intention to acquire control and no related process or assessment is underway. The company identified factual inaccuracies in the report inconsistent with its recent public disclosures.

    View Filing

    Nexalin Technology, Inc.

    NXL
    10-K

    Filing ID: 786834 • Mar 25, 2026, 12:00 PM ET

    •

    Revenues grew 79% YoY to $302K in FY 2025.

    •

    Net loss $8.2M, EPS -$0.50 vs prior -$7.6M, -$0.83.

    •

    Operating cash use -$5.0M; financing provided $5.2M.

    Nexalin Technology, Inc. (NXL) reported FY 2025 revenues of $302K, up 79% YoY from $169K in 2024, driven by increased device sales ($136K vs $56K) and equipment ($89K vs $38K), including related party revenue of $50K. Gross profit rose 82% to $240K, with gross margin improving to 80% from 78%. However, total operating expenses increased 9% to $8.6M, leading to a loss from operations of -$8.4M, up 8% from -$7.8M. Net loss widened slightly to -$8.2M from -$7.6M, with EPS improving to -$0.50 from -$0.83 due to higher shares outstanding (16.4M vs 9.2M). Cash used in operations was -$5.0M, offset by $5.2M financing inflows, resulting in cash increase to $655K and short-term investments of $3.1M. Total assets stood at $4.6M with equity $3.7M. The company advanced FDA interactions for Gen-2 SYNC and Gen-3 HALO devices, but faces going concern doubts amid ongoing losses and Nasdaq compliance issues.

    View Filing

    Korea Electric Power Corporation

    KEP
    6-K

    Filing ID: 786836 • Mar 25, 2026, 12:10 PM ET

    Annual General Meeting Results and FY2025 Financial Statements Approval
    HIGH
    •

    All three AGM agendas approved: financial statements (99.1%), director remuneration ceiling (99.7%), Articles amendments (99.9%) out of 511,345,965 attendant shares from 641,964,077 outstanding

    •

    FY2025 revenue 97,429,346 million won vs 93,398,896 million won prior year

    •

    FY2025 profit for the year 8,666,656 million won vs 3,621,968 million won prior year

    At the March 25, 2026 annual general meeting, Korea Electric Power Corporation shareholders approved FY2025 financial statements, maximum aggregate director remuneration of 2,207,869 thousand won for 2026, and amendments to the Articles of Incorporation, all with 99.1% to 99.9% support. FY2025 consolidated results showed revenue of 97,429,346 million won and profit for the year of 8,666,656 million won.

    View Filing

    Mag Magna Corp.

    MGNC
    8-K

    Filing ID: 786832 • Mar 25, 2026, 11:40 AM ET

    Fraudulent Press Release Denial
    LOW
    •

    Fraudulent press release headline: 'MGNC Announces Strategic Acquisition of Large-Scale Poultry Farming Enterprise to Accelerate Commercial Expansion and Revenue Growth'

    •

    Company did not authorize inclusion of ticker MGNC in Fraudulent Release

    •

    Poultry business operations abandoned effective December 24, 2025, upon change-in-control transaction

    Mag Magna Corp. was notified of a fraudulent press release on March 25, 2026, claiming a strategic acquisition of a large-scale poultry farming enterprise, which the Company did not authorize. The Company abandoned poultry operations effective December 24, 2025, focuses solely on rare earth elements mining, and demanded the fraudulent release be stricken, advising no reliance on it.

    View Filing

    Ryanair Holdings plc

    RYAAY
    6-K

    Filing ID: 786835 • Mar 25, 2026, 12:00 PM ET

    Major Holdings Notification (TR-1)
    MEDIUM
    •

    Artisan Partners Limited Partnership crossed above 4% threshold on 2026-03-23

    •

    Current voting rights: 4.022% (42,091,516 direct shares)

    •

    Previous position: 3.996%

    Ryanair Holdings plc disclosed a Form 6-K with a TR-1 notification from Artisan Partners Limited Partnership indicating it crossed above the 4% voting rights threshold to 4.022% (42,091,516 shares, ISIN IE00BYTBXV33) on March 23, 2026, up from 3.996%. The notification was received by the issuer on March 25, 2026.

    View Filing

    Ryanair Holdings plc

    RYAOF
    6-K

    Filing ID: 786835 • Mar 25, 2026, 12:00 PM ET

    Major Holdings Notification (TR-1)
    MEDIUM
    •

    Artisan Partners Limited Partnership crossed above 4% threshold on 2026-03-23

    •

    Current voting rights: 4.022% (42,091,516 direct shares)

    •

    Previous position: 3.996%

    Ryanair Holdings plc disclosed a Form 6-K with a TR-1 notification from Artisan Partners Limited Partnership indicating it crossed above the 4% voting rights threshold to 4.022% (42,091,516 shares, ISIN IE00BYTBXV33) on March 23, 2026, up from 3.996%. The notification was received by the issuer on March 25, 2026.

    View Filing

    Muzinich BDC, Inc.

    8-K

    Filing ID: 786837 • Mar 25, 2026, 12:10 PM ET

    Executive Changes
    HIGH
    5.02
    •

    Jeffrey Youle stepping down as President and CEO effective April 1, 2026

    •

    Paul Fehre stepping down as CFO and Treasurer effective April 1, 2026

    •

    Cheryl Rivkin appointed CEO effective April 1, 2026, resigning as Secretary

    Muzinich BDC, Inc. disclosed that on March 23, 2026, President and CEO Jeffrey Youle and CFO and Treasurer Paul Fehre informed the Board they are stepping down effective April 1, 2026, with no disagreements on operations, policies, or practices. The Board approved appointments of Cheryl Rivkin as CEO, Jens Ernberg as President, Rocco DelGuercio as CFO and Treasurer, and Susan Cohen as Secretary, all effective April 1, 2026.

    View Filing

    Muzinich Corporate Lending Income Fund, Inc.

    8-K

    Filing ID: 786838 • Mar 25, 2026, 12:10 PM ET

    Executive Changes
    HIGH
    5.02
    •

    Jeffrey Youle stepping down as CEO effective April 1, 2026

    •

    Paul Fehre stepping down as CFO and Treasurer effective April 1, 2026

    •

    Cheryl Rivkin appointed CEO effective April 1, 2026, resigning as Secretary

    Muzinich Corporate Lending Income Fund, Inc. disclosed a leadership transition effective April 1, 2026, with CEO Jeffrey Youle and CFO/Treasurer Paul Fehre stepping down without disagreements, to be succeeded by Cheryl Rivkin as CEO, Jens Ernberg as President, Rocco DelGuercio as CFO/Treasurer, and Susan Cohen as Secretary. Departing executives continue as Board members and in Muzinich roles.

    View Filing
    1...531
    Go toof 532

    Market

    • Top Movers
    • Companies
    • Concepts

    SEC Filings

    • AI Filing Analysis
    • Financial Reports
    • Current Reports
    • IPO Filings

    Ownership

    • Institutional Holdings
    • Insider Trading

    About

    • Data updates every 5 min
    • SEC EDGAR Source
    © 2025–2026 StockGist|Information only, not investment advice